[Acute myeloid leukemia (AML) in adults. Further development of therapy based on clinical phase II and phase III studies].
By a review of relevant clinical studies on adult AML no substantial progress can be seen in the eighties so far. After the development of successful chemotherapy regimens during the seventies, further improvement can only be expected in small steps. Clinical studies, therefore, should concentrate on the analysis of the different components and new elements of treatment in order to utilize and combine them more effectively. For this purpose, a standardization of treatment and, for many aspects, a randomized comparison is inevitable. Thus, the role of monthly maintenance as well as of a special type of immunotherapy could be elucidated for the first time by our multicenter trial.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D011379:Prognosis; D011897:Random Allocation
Akute myeloische Leukämie (AML) des Erwachsenen. Weiterentwicklung der Therapie auf der Basis klinischer Phase-II-und Phas-III-Studien.